Navigation Links
Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
Date:6/3/2013

PLANTATION, Fla., June 3, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) announced today the award of a sub-contract from Emergent BioSolutions for GBI to conduct some early stage proof-of-concept feasibility process development to investigate concentrating AVA filtrate for storage before the downstream process for BioThrax® (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the protection against anthrax disease.  Anthrax is a potentially deadly disease that is caused by the bacteria Bacillus anthracis.  While Anthrax does not spread directly from one infected animal or person to another, it is spread by endospores that are able to survive in harsh conditions for long periods of time, and those spores can lie dormant for years and possibly decades. When the spores are inhaled, ingested, or come into contact with a skin lesion on a host, they may germinate and multiply rapidly in both humans and animals. 

"We're excited about the opportunity to contribute our protein purification as well as processing experience and expertise which have been developed and refined over the last 20 years," noted Muctarr Sesay , PhD, Vice President of Process Development at GBI. "Our goal is to develop process parameters that are amenable to routine GMP production and large-scale manufacturing in an effort to contribute to the production of BioThrax at large scale."

Heidi Nielsen , Process Development Engineer for the Biodefense Division of Emergent BioSolutions said, "This phase of process development is critical to our project. We chose to work with Goodwin Biotechnology based on their Quality Systems and experience with large scale, GMP-compliant protein purification and processing."

About Goodwin Biotechnology, Inc.
Goodwin Biotechnology is a world-class CMO that offers a Single Source Solution™ through partnerships with clients for cell line development or exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines and Antibody Drug Conjugates (ADCs) for early and late stage clinical trials. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies as well as a road map to meet the highest quality product requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical approval pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent contract manufacturer, GBI has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Additional information may be found at www.GoodwinBio.com.

For more information on the process development and GMP manufacturing of biologics, please contact Goodwin Biotechnology:
Robin McCallum
Business Development Manager
(954) 327-9656
RMcCallum@GoodwinBio.com


'/>"/>
SOURCE Goodwin Biotechnology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology is a Three-Category Winner in the 2012 CMO Leadership Awards
2. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
5. Antibiotics and Biotechnology Take Center Stage at Food Dialogues Event
6. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Agricultural Biotechnology: Emerging Technologies and Global Markets
9. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
10. Pharmaceutical Market & Biotechnology Industry 2013 Outlook in New Research Reports at ReportsnReports.com
11. Financial Assessment of the Global Pharmaceutical and Biotechnology Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
Breaking Medicine News(10 mins):